Susquehanna International Group, LLP Uni Qure N.V. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.78 - $10.12 $87,696 - $234,783	-23,200 Reduced 6.08%	358,200 $1.77 Million
Q2 2024 Aug 15, 2024	SELL	$4.39 - $5.43 $438,560 - $542,457	-99,900 Reduced 20.76%	381,400 $1.71 Million
Q1 2024 May 07, 2024	BUY	$4.82 - $6.93 $1.54 Million - $2.21 Million	318,700 Added 196.0%	481,300 $2.5 Million
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $617,048 - $906,392	-109,600 Reduced 40.26%	162,600 $1.1 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $33,550 - $59,150	5,000 Added 1.87%	272,200 $1.83 Million
Q2 2023 Aug 11, 2023	BUY	$11.12 - $22.2 $1.85 Million - $3.69 Million	166,200 Added 164.55%	267,200 $3.06 Million
Q1 2023 May 16, 2023	SELL	$18.7 - $23.07 $3.14 Million - $3.88 Million	-168,000 Reduced 62.45%	101,000 $2.03 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $41,676 - $62,836	2,300 Added 0.86%	269,000 $6.1 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $782,778 - $1.18 Million	46,100 Added 20.9%	266,700 $5 Million
Q2 2022 Aug 15, 2022	BUY	$13.15 - $20.45 $1.46 Million - $2.28 Million	111,300 Added 101.83%	220,600 $4.11 Million
Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $138,130 - $204,250	-9,500 Reduced 8.0%	109,300 $1.98 Million
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $1.49 Million - $2.64 Million	-73,400 Reduced 38.19%	118,800 $2.46 Million
Q3 2021 Nov 15, 2021	BUY	$26.01 - $38.22 $1.68 Million - $2.47 Million	64,500 Added 50.51%	192,200 $6.15 Million
Q2 2021 Aug 11, 2021	BUY	$29.97 - $37.17 $1.17 Million - $1.45 Million	39,000 Added 43.97%	127,700 $3.93 Million
Q1 2021 May 17, 2021	BUY	$29.24 - $42.03 $359,652 - $516,969	12,300 Added 16.1%	88,700 $2.99 Million
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $11.7 Million - $16.7 Million	-330,200 Reduced 81.21%	76,400 $2.76 Million
Q3 2020 Nov 16, 2020	BUY	$35.98 - $47.66 $1.93 Million - $2.56 Million	53,700 Added 15.22%	406,600 $15 Million
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $4.84 Million - $7.28 Million	107,400 Added 43.75%	352,900 $15.9 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $3.09 Million - $5.72 Million	77,300 Added 45.96%	245,500 $11.6 Million
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $12.5 Million - $25.1 Million	-335,800 Reduced 66.63%	168,200 $12.1 Million
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $3.83 Million - $7.47 Million	-97,300 Reduced 16.18%	504,000 $19.8 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $7.69 Million - $12 Million	145,800 Added 32.01%	601,300 $47 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $10.1 Million - $25.2 Million	367,700 Added 418.79%	455,500 $27.2 Million
Q4 2018 Feb 14, 2019	BUY	$22.8 - $33.93 $579,120 - $861,822	25,400 Added 40.71%	87,800 $2.53 Million
Q3 2018 Nov 14, 2018	SELL	$29.75 - $43.08 $2.04 Million - $2.95 Million	-68,500 Reduced 52.33%	62,400 $2.27 Million
Q2 2018 Aug 14, 2018	SELL	$21.96 - $39.94 $1.7 Million - $3.1 Million	-77,600 Reduced 37.22%	130,900 $4.95 Million
Q1 2018 May 15, 2018	BUY	$17.1 - $26.61 $2.64 Million - $4.11 Million	154,300 Added 284.69%	208,500 $4.9 Million
Q4 2017 Feb 14, 2018	BUY	$9.47 - $19.59 $513,274 - $1.06 Million	54,200	54,200 $1.06 Million

Others Institutions Holding QURE

# of Institutions

153

Shares Held

41M

Call Options Held

925K

Put Options Held

617K

Vestal Point Capital, LP New York, NY

4.75M
Shares

$27.5 Million
1.78% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

2.78M
Shares

$16.1 Million
0.81% of portfolio
Boxer Capital, LLC San Diego, CA

2.23M
Shares

$12.9 Million
0.58% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.19M
Shares

$12.7 Million
0.01% of portfolio
Abrdn PLC

1.93M
Shares

$11.1 Million
0.02% of portfolio

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account